View Older Stories View More Recent Stories
-
Johnson & Johnson (JNJ) PT Raised to $166 at Barclays
-
Johnson & Johnson (JNJ) PT Lowered to $158 at Bernstein Amid 'Tough Setup for 2025'
-
Johnson & Johnson (JNJ) PT Lowered to $155 at Stifel
-
Johnson & Johnson (JNJ) PT Lowered to $159 at BofA Securities
-
Goldman Sachs Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
Biodexa Pharmaceuticals (BDRX) Appoints Gary A. Shangold as Chief Medical Officer
-
Raymond James Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) Tops Q4 EPS by 2c; offers 2025 guidance
-
Johnson & Johnson (JNJ) call put ratio 3.5 calls to 1 put with a focus on January 24 weekly 155 calls into quarter results
-
Johnson & Johnson (JNJ) Announces SPRAVATO Approved in the U.S.
-
Johnson & Johnson (JNJ) calls more active than puts into quarter results
-
Johnson & Johnson (JNJ): NDA initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive
-
Morgan Stanley Downgrades Intra-Cellular Therapies (ITCI) to Equalweight
-
Morgan Stanley Reiterates Equalweight Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) Acquires Intra-Cellular Therapies (ITCI) for $132/sh Cash or $14.6B
-
J&J (JNJ) in Talks to Buy Intra-Cellular (ITCI) - Bloomberg
-
Johnson & Johnson (JNJ) Confirms Temporary Pause of US Eval and Varipulse Cases - Bloomberg
-
Johnson & Johnson's (JNJ) Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease
-
Johnson & Johnson (JNJ) Announces RYBREVANT plus LAZCLUZE show statistically significant and clinically meaningful improvement in overall survival versus osimertinib
-
FDA Approves Celltrion's Steqeyma, Biosimilar to J&J's (JNJ) Stelara
-
This consumer stock is a Top Pick for 2025 at Jefferies
-
Johnson & Johnson (JNJ) Announces FDA Issues CRL For Rybrevant BLA
-
RBC Capital on Johnson & Johnson (JNJ): 'Oncology Portfolio Built for Long-Term Growth'
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
Johnson & Johnson (JNJ) seeks U.S. FDA approval for first pediatric indications for TREMFYA
-
Johnson & Johnson (JNJ) seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
-
Johnson & Johnson (JNJ) reports icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
-
Johnson & Johnson (JNJ) call put ratio 1 call to 1.9 puts
-
Johnson & Johnson (JNJ) reports nipocalimab demonstrated significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
-
Johnson & Johnson (JNJ): Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren
-
Johnson & Johnson (JNJ) submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
-
Johnson & Johnson (JNJ): TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
-
Starboard Value Builds Stake In Tylenol-Maker Kenvue - WSJ
-
Johnson & Johnson (JNJ) PT Raised to $181 at RBC Capital
-
Johnson & Johnson (JNJ) PT Raised to $170 at Stifel
-
Citi Reiterates Buy Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study
-
Johnson & Johnson (JNJ) Tops Q3 EPS by 23c, Beats on Revenue
-
Johnson & Johnson reports earnings ahead of the open. Here's what to know
-
Johnson & Johnson (JNJ) October option implied volatility into quarter results
-
Johnson & Johnson (JNJ) October 160 straddle priced into quarter results
-
Johnson & Johnson (JNJ) October 160 straddle priced into quarter results
-
Johnson & Johnson's (JNJ) TREMFYA demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis
-
Stifel Reiterates Hold Rating on Johnson & Johnson (JNJ) on V-Wave acquisition
-
Wells Fargo Reiterates Equal Weight Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) Completes Acquisition of V-Wave
-
Johnson & Johnson (JNJ) reports ERLEADA demonstrated statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration
-
Johnson & Johnson (JNJ) files for U.S. FDA approval of DARZALEX FASPRO-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
-
Johnson & Johnson (JNJ) Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
-
Johnson & Johnson (JNJ) reports CARVYKTI is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second lin
